Barchart.com
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
9.91 -0.69 (-6.51%) 04/01/25 [NASDAQ]
9.00 x 100 9.99 x 1,000
Realtime by (Cboe BZX)
9.00 x 100 9.99 x 1,000
Realtime - - (-) -
News & Headlines for Tue, Apr 1st, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
uniQure Announces 2024 Financial Results and Highlights Recent Company Progress GlobeNewswire - Thu Feb 27, 6:05AM CST

QURE : 9.91 (-6.51%)
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease GlobeNewswire - Mon Feb 3, 6:05AM CST

QURE : 9.91 (-6.51%)
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS GlobeNewswire - Thu Jan 30, 6:37AM CST

QURE : 9.91 (-6.51%)
uniQure Announces Pricing of its Public Offering GlobeNewswire - Wed Jan 8, 6:05AM CST

QURE : 9.91 (-6.51%)
uniQure Announces Proposed Public Offering GlobeNewswire - Tue Jan 7, 3:49PM CST

QURE : 9.91 (-6.51%)
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? Motley Fool - Sun Dec 15, 2024

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's...

QURE : 9.91 (-6.51%)
uniQure Announces FDA Agreement on Accelerated Approval Pathway for AMT-130 in Huntington’s Disease Quiver Quantitative, Inc. - Tue Dec 10, 2024

The FDA supports uniQure's AMT-130 for Huntington's disease under an Accelerated Approval pathway using existing study data.Quiver AI SummaryuniQure N.V. announced that the U.S. Food and Drug Administration...

QURE : 9.91 (-6.51%)
uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More Optimistic Stocktwits - Tue Dec 10, 2024

uniQure’s AMT-130 previously received a regenerative medicine advanced therapy designation from the FDA in May.

QURE : 9.91 (-6.51%)
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease GlobeNewswire - Tue Dec 10, 2024

QURE : 9.91 (-6.51%)
uniQure N.V. Initiates Phase I/IIa Clinical Trial for AMT-260 in Refractory Mesial Temporal Lobe Epilepsy Quiver Quantitative, Inc. - Thu Nov 21, 2024

uniQure initiates GenTLE trial, dosing first patient with AMT-260 for refractory mesial temporal lobe epilepsy treatment.Quiver AI SummaryuniQure N.V. announced the dosing of the first patient in its GenTLE...

QURE : 9.91 (-6.51%)

Barchart Exclusives

Ford Stock Has a Fatter Dividend Yield Than GM, But Is It a Better Buy? Barchart - Tue Apr 1, 6:30PM CDT
Auto stocks have been hammered by Trump's tariffs, and Ford now yields around 6%. While Ford's dividend yield is around 5 times GM's, F needs to up its game for the stock to deliver capital gains. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies
Wed, Apr 02, 2025 5:00 PM UTC
Reserve Your Spot